Skip Nav Destination
Issues
1 April 2022
-
Cover Image
Cover Image
Representative hematoxylin and eosin stain of resected tumor tissue from a patient with head and neck squamous cell carcinoma after treatment with the PD-1 inhibitor, pembrolizumab. No treatment effect, defined as tumor necrosis with associated histiocytic inflammation and/or giant cell reaction to keratinaceous debris, was observed in this patient, classifying the patient as a nonresponder. For details, see the article by Wise-Draper and colleagues on page 1345 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
Reviews
Clinical Trials: Targeted Therapy
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Cynthia X. Ma; Jingqin Luo; Rachel A. Freedman; Timothy J. Pluard; Julie R. Nangia; Janice Lu; Frances Valdez-Albini; Melody Cobleigh; Jason M. Jones; Nancy U. Lin; Eric P. Winer; P. Kelly Marcom; Shana Thomas; Jill Anderson; Brittney Haas; Leslie Bucheit; Richard Bryce; Alshad S. Lalani; Lisa A. Carey; Matthew P. Goetz; Feng Gao; Gretchen Kimmick; Mark D. Pegram; Matthew J. Ellis; Ron Bose
Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
Suzanne George; Margaret von Mehren; Jonathan A. Fletcher; Jichao Sun; Sen Zhang; Justin R. Pritchard; John Graeme Hodgson; David Kerstein; Victor M. Rivera; Frank G. Haluska; Michael C. Heinrich
Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
Krina K. Patel; Jatin J. Shah; Lei Feng; Hans C. Lee; Elisabet M. Manasanch; Jasper Olsem; Ashley Morphey; Xiao Jiao Huo; Sheeba K. Thomas; Qaiser Bashir; Muzaffar H. Qazilbash; Donna M. Weber; Robert Z. Orlowski
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
Jennifer R. Diamond; Valentina Boni; Emerson Lim; Grzegorz Nowakowski; Raul Cordoba; Daniel Morillo; Ray Valencia; Isabelle Genvresse; Claudia Merz; Oliver Boix; Melanie M. Frigault; Joy M. Greer; Ahmed M. Hamdy; Xin Huang; Raquel Izumi; Harvey Wong; Victor Moreno
Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study
Alex F. Herrera; Manish R. Patel; John M. Burke; Ranjana Advani; Bruce D. Cheson; Jeff P. Sharman; Elicia Penuel; Andrew G. Polson; Chen Di Liao; Chunze Li; Eva Schuth; Anjali Vaze; Divya Samineni; Rebecca Elstrom; James Cooper; Catherine Diefenbach
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
George D. Demetri; Filippo De Braud; Alexander Drilon; Salvatore Siena; Manish R. Patel; Byoung Chul Cho; Stephen V. Liu; Myung-Ju Ahn; Chao-Hua Chiu; Jessica J. Lin; Koichi Goto; Jeeyun Lee; Lyudmila Bazhenova; Thomas John; Marwan Fakih; Sant P. Chawla; Rafal Dziadziuszko; Takashi Seto; Sebastian Heinzmann; Bethany Pitcher; David Chen; Timothy R. Wilson; Christian Rolfo
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Maria R. Baer; Aksinija A. Kogan; Søren M. Bentzen; Tian Mi; Rena G. Lapidus; Vu H. Duong; Ashkan Emadi; Sandrine Niyongere; Casey L. O'Connell; Benjamin A. Youngblood; Stephen B. Baylin; Feyruz V. Rassool
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Nigel Bundred; Nuria Porta; Adrian Murray Brunt; Angela Cramer; Andrew Hanby; Abeer M. Shaaban; Emad A. Rakha; Anne Armstrong; Ramsey I. Cutress; David Dodwell; Marie A. Emson; Abigail Evans; Sue M. Hartup; Kieran Horgan; Sarah E. Miller; Stuart A. McIntosh; James P. Morden; Jay Naik; Sankaran Narayanan; Jane Ooi; Anthony I. Skene; David A. Cameron; Judith M. Bliss
Clinical Trials: Immunotherapy
Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer
Robert L. Ferris; Jessica Moskovitz; Sheryl Kunning; Ayana T. Ruffin; Carly Reeder; James Ohr; William E. Gooding; Seungwon Kim; Brian J. Karlovits; Dario A.A. Vignali; Umamaheswar Duvvuri; Jonas T. Johnson; Daniel Petro; Dwight E. Heron; David A. Clump; Tullia C. Bruno; Julie E. Bauman
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma
Trisha M. Wise-Draper; Shuchi Gulati; Sarah Palackdharry; Benjamin H. Hinrichs; Francis P. Worden; Matthew O. Old; Neal E. Dunlap; John M. Kaczmar; Yash Patil; Muhammed Kashif Riaz; Alice Tang; Jonathan Mark; Chad Zender; Ann M. Gillenwater; Diana Bell; Nicky Kurtzweil; Maria Mathews; Casey L. Allen; Michelle L. Mierzwa; Keith Casper; Roman Jandarov; Mario Medvedovic; J. Jack Lee; Nusrat Harun; Vinita Takiar; Maura Gillison
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
Daniel M. Girardi; Scot A. Niglio; Amir Mortazavi; Rosa Nadal; Primo Lara; Sumanta K. Pal; Biren Saraiya; Lisa Cordes; Lisa Ley; Olena Sierra Ortiz; Jacqueline Cadena; Carlos Diaz; Hadi Bagheri; Bernadette Redd; Seth M. Steinberg; Rene Costello; Keith S. Chan; Min-Jung Lee; Sunmin Lee; Yunkai Yu; Sandeep Gurram; Heather J. Chalfin; Vladimir Valera; William D. Figg; Maria Merino; Antoun Toubaji; Howard Streicher; John J. Wright; Elad Sharon; Howard L. Parnes; Yang-Min Ning; Donald P. Bottaro; Liang Cao; Jane B. Trepel; Andrea B. Apolo
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Ana-Marija Grisic; Wenyuan Xiong; Lénaïg Tanneau; Siv Jönsson; Lena E. Friberg; Mats O. Karlsson; Haiqing Dai; Jenny Zheng; Pascal Girard; Akash Khandelwal
Precision Medicine and Imaging
Validation of Anticorrelated TGFβ Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy
Ines Guix; Qi Liu; Miquel Angel Pujana; Patrick Ha; Josep Piulats; Isabel Linares; Ferran Guedea; Jian-Hua Mao; Ann Lazar; Jocelyn Chapman; Sue S. Yom; Alan Ashworth; Mary Helen Barcellos-Hoff
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
Joanne L. Blum; A. Douglas Laird; Jennifer K. Litton; Hope S. Rugo; Johannes Ettl; Sara A. Hurvitz; Miguel Martin; Henri H. Roché; Kyung-Hun Lee; Annabel Goodwin; Ying Chen; Silvana Lanzalone; Jijumon Chelliserry; Akos Czibere; Julia F. Hopkins; Lee A. Albacker; Lida A. Mina
Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity
Kathryn M. Tully; Salomon Tendler; Lukas M. Carter; Sai Kiran Sharma; Zachary V. Samuels; Komal Mandleywala; Joshua A. Korsen; Avelyn Mae Delos Reyes; Alessandra Piersigilli; William D. Travis; Triparna Sen; Nagavarakishore Pillarsetty; John T. Poirier; Charles M. Rudin; Jason S. Lewis
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Louisa R. Hoes; Jade M. van Berge Henegouwen; Hanneke van der Wijngaart; Laurien J. Zeverijn; Daphne L. van der Velden; Joris van de Haar; Paul Roepman; Wendy J. de Leng; Anne M.L. Jansen; Erik van Werkhoven; Vincent van der Noort; Alwin D.R. Huitema; Eelke H. Gort; Jan Willem B. de Groot; Emile D. Kerver; Derk Jan de Groot; Frans Erdkamp; Laurens V. Beerepoot; Mathijs P. Hendriks; Egbert F. Smit; Winette T.A. van der Graaf; Carla M.L. van Herpen; Mariette Labots; Ann Hoeben; Hans Morreau; Martijn P. Lolkema; Edwin Cuppen; Hans Gelderblom; Henk M.W. Verheul; Emile E. Voest
Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
C. Benedikt Westphalen; Alexander D. Fine; Fabrice André; Shridar Ganesan; Volker Heinemann; Etienne Rouleau; Clare Turnbull; Luis Garcia Palacios; Jorge-Antonio Lopez; Ethan S. Sokol; Joaquin Mateo
Translational Cancer Mechanisms and Therapy
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
Andrey A. Yurchenko; Oltin T. Pop; Meriem Ighilahriz; Ismael Padioleau; Fatemeh Rajabi; Hayley J. Sharpe; Nicolas Poulalhon; Brigitte Dreno; Amir Khammari; Marc Delord; Antonio Alberti; Nadem Soufir; Maxime Battistella; Samia Mourah; Fanny Bouquet; Ariel Savina; Andrej Besse; Max Mendez-Lopez; Florent Grange; Sandrine Monestier; Laurent Mortier; Nicolas Meyer; Caroline Dutriaux; Caroline Robert; Philippe Saiag; Florian Herms; Jerome Lambert; Frederic J. de Sauvage; Nicolas Dumaz; Lukas Flatz; Nicole Basset-Seguin; Sergey I. Nikolaev
A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer
Emanuela Dylgjeri; Vishal Kothari; Ayesha A. Shafi; Galina Semenova; Peter T. Gallagher; Yi F. Guan; Angel Pang; Jonathan F. Goodwin; Swati Irani; Jennifer J. McCann; Amy C. Mandigo; Saswati Chand; Christopher M. McNair; Irina Vasilevskaya; Matthew J. Schiewer; Costas D. Lallas; Peter A. McCue; Leonard G. Gomella; Erin L. Seifert; Jason S. Carroll; Lisa M. Butler; Jeff Holst; William K. Kelly; Karen E. Knudsen
NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy
Yoshihiro Otani; Ji Young Yoo; Cole T. Lewis; Samantha Chao; Jessica Swanner; Toshihiko Shimizu; Jin Muk Kang; Sara A. Murphy; Kimberly Rivera-Caraballo; Bangxing Hong; Joseph C. Glorioso; Hiroshi Nakashima; Sean E. Lawler; Yeshavanth Banasavadi-Siddegowda; John D. Heiss; Yuanqing Yan; Guangsheng Pei; Michael A. Caligiuri; Zhongming Zhao; E. Antonio Chiocca; Jianhua Yu; Balveen Kaur
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.